Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLP-Polio Vaccine in Infants and Toddlers
NCT06577298Phase 2Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vlp-polio in poliomyelitis (14 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Percentage of participants with solicited adverse events and Seroconversion rate of neutralizing antibodies against Sabin and wild-type poliovirus type 1, 2, and 3. Started Dec 2024; status: active, not recruiting.
02
Drugs
vlp-polio
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT06577298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577298.